NeuroSense Therapeutics Ltd. Logo

NeuroSense Therapeutics Ltd.

A late-clinical stage company developing drugs for neurodegenerative diseases like ALS.

NRSN | US

Overview

Corporate Details

ISIN(s):
IL0011809592 (+1 more)
LEI:
Country:
United States of America
Address:
11 HAMENOFIM ST., 4672562 HERZLIYA

Description

NeuroSense Therapeutics Ltd. is a late-clinical stage drug development company focused on discovering and developing treatments for severe neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS). The company's strategy is to create combined therapies that target multiple pertinent mechanisms involved in these complex conditions. Its lead drug candidate, PrimeC, is a unique fixed-dose combination of ciprofloxacin and celecoxib. Following a successful Phase 2b clinical trial (PARADIGM) that demonstrated a significant impact on slowing disease progression, NeuroSense is advancing PrimeC into a pivotal Phase 3 study. PrimeC has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company is also exploring therapies for other neurodegenerative diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all NeuroSense Therapeutics Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NeuroSense Therapeutics Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NeuroSense Therapeutics Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Cuorips Inc. Logo
Develops iPS cell-derived therapies and provides cell processing contract services.
Japan
4894
Cuprina Holdings (Cayman) LTD Logo
Biomedical firm developing wound care biotherapy and cosmeceutical products.
United States of America
CUPR
Curanex Pharmaceuticals Inc Logo
Develops botanical drugs for inflammatory diseases like ulcerative colitis.
United States of America
CURX
Curasight A/S Logo
A clinical-stage biotech developing a theranostic platform for cancer diagnosis and treatment.
Denmark
CURAS
Curevac Logo
A biopharmaceutical company developing therapies based on messenger RNA (mRNA) technology.
Germany
CVAC
CureVac N.V. Logo
A biopharmaceutical company developing mRNA-based medicines for a range of diseases.
United States of America
CVAC
CURIS INC Logo
Biotechnology company developing and commercializing therapeutics for cancer treatment.
United States of America
CRIS
Curocell Inc. Logo
A clinical-stage biotech developing CAR-T therapies for blood cancers.
South Korea
372320
CYBIN INC. Logo
A late-stage neuropsychiatry company developing psychedelic-based therapeutics.
United States of America
CYBN
Cyclerion Therapeutics, Inc. Logo
Develops personalized biofeedback therapies for treatment-resistant depression.
United States of America
CYCN

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.